Vedolizumab induction therapy for inflammatory bowel disease in clinical practice - a nationwide consecutive German cohort study

The Expenditures for Academic Inpatient Care of Inflammatory Bowel Disease Patients Are Almost Double Compared with Average Academic Gastroenterology and Hepatology Cases and Not Fully Recovered by Diagnosis-Related Group (DRG) Proceeds

(2016) Daniel C. Baumgart et al.   PLoS One

Systematic review and meta-analysis: opportunistic infections and malignancies during treatment with anti-integrin antibodies in inflammatory bowel disease

(2015) P. Luthra et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Pseudomonas Meningitis During Vedolizumab Therapy for Crohn’s Disease

(2015) Brigid S. Boland et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Tu1368 Vedolizumab in Inflammatory Bowel Disease, the First Experience From the Swedish IBD Registry (SWIBREG)

(2015) Carl Eriksson et al.   GASTROENTEROLOGY

Tu1369 Vedolizumab Efficacy and Safety in a Tertiary Care IBD Clinical Practice

(2015) Emily Vivio et al.   GASTROENTEROLOGY

Vedolizumab for Induction and Maintenance of Remission in Ulcerative Colitis

(2015) Mahmoud H. Mosli et al.   INFLAMMATORY BOWEL DISEASES

Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients

(2015) Edward Shelton et al.   INFLAMMATORY BOWEL DISEASES

Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed

(2014) Bruce E. Sands et al.   GASTROENTEROLOGY

Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results

(2014) Tim Wyant et al.   GUT

Smoking in inflammatory bowel disease: Impact on disease course and insights into the aetiology of its effect

(2014) Gareth C. Parkes et al.   Journal of Crohns & Colitis

Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial

(2014) Séverine Vermeire et al.   LANCET

Comparative Efficacy of Biologic Therapy in Biologic-Naïve Patients With Crohn Disease: A Systematic Review and Network Meta-analysis

(2014) Siddharth Singh et al.   MAYO CLINIC PROCEEDINGS

Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment

(2013) Cornelia Tillack et al.   GUT

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

(2013) Brian G. Feagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

(2013) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Review article: ulcerative colitis, smoking and nicotine therapy

(2012) P. C. Lunney et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Patients Enrolled in Randomized Controlled Trials Do Not Represent the Inflammatory Bowel Disease Patient Population

(2012) Christina Ha et al.   Clinical Gastroenterology and Hepatology

Ulcerative colitis

(2012) Ingrid Ordás et al.   LANCET

Crohn's disease

(2012) Daniel C Baumgart et al.   LANCET

The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study

(2011) S. Vermeire et al.   GUT

Frequency, phenotype, outcome, and therapeutic impact of skin reactions following initiation of adalimumab therapy: Experience from a consecutive cohort of inflammatory bowel disease patients

(2011) Daniel C. Baumgart et al.   INFLAMMATORY BOWEL DISEASES

Targeting leukocyte migration and adhesion in Crohn’s disease and ulcerative colitis

(2011) Saskia Thomas et al.   INFLAMMOPHARMACOLOGY

Correlation Between the Crohn's Disease Activity and Harvey–Bradshaw Indices in Assessing Crohn's Disease Severity

(2010) Severine Vermeire et al.   Clinical Gastroenterology and Hepatology

The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti- 4 7 Integrin Therapeutic Antibody in Development for Inflammatory Bowel Diseases

(2009) D. Soler et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Use of the noninvasive components of the mayo score to assess clinical response in Ulcerative Colitis

(2008) James D. Lewis et al.   INFLAMMATORY BOWEL DISEASES